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Available online 8 August 2019Background: Breath tests may diagnose tuberculosis (TB) through detecting speciﬁc volatile organic compounds
produced byMycobacterium tuberculosis or the infected host.
Methods: To estimate the diagnostic accuracy of breath test with electronic-nose and other devices against
culture or other tests for TB, we screened multiple databases until January 6, 2019.
Findings:We included fourteen studies, with 1715 subjects in the analysis. The pooled sensitivity and speciﬁcity
of electronic-nose were 0.93 (95% CI 0.82–0.97) and 0.93 (95% CI 0.82–0.97), respectively, and no heterogeneity
was found. The sensitivity and speciﬁcity of other breath test devices ranged from 0.62 to 1.00, and 0.11 to 0.84,
respectively.
Interpretation: The low tomoderate evidence of these studies shows that breath tests can diagnose TB accurately,
however, to give a real-time test result, additional development is needed. Research should also focus on sputum
smear negative TB, children, and the positioning of breath testing in the diagnostic work ﬂow.
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Accuracy1. Introduction by molecular assays as the line probe assays (LPAs), or detection of
acid-fast bacilli by sputum smear microscopy (SSM) if culture or LPAsTuberculosis (TB) is the leading infectious cause of morbidity and
mortality globally [1]. It spreads easily by air, with inhalation of infected
droplets exhaled, coughed or sneezed by individuals affected with con-
tagious forms of pulmonary TB. Approximately 23% of the world's pop-
ulation is infected with TB bacteria, and 5–15% will suffer from TB at
some point in time [1,2]. Diagnostic delay is a major concern in TB con-
trol: there is an average loss of one to three months delay between the
ﬁrst day that patients present to the health care system, and the mo-
ment of diagnosis [3,4]. In 2017, there was a gap of 3·6million between
notiﬁcations of new cases and the estimated number of incident cases
[1], indicating a huge underreporting and under-diagnosis of TB cases.
In response, the World Health Organization (WHO) launched an initia-
tive to detect many more people with TB in the next few years [1].
The WHO criteria for pulmonary TB (PTB) diagnosis include clinical
symptoms and isolation of M. tuberculosis from sputum by culture or& Tuberculosis Unit, University
ox 30 001, 9700 RB Groningen,
Werf).
. This is an open access article underis unavailable, or – for smear-negative PTB patients - with chest radiog-
raphy (CXR) showing abnormalities consistent with active PTB [5].
Meanwhile, for extra-pulmonary TB (EPTB), the diagnosis is based on
at least one specimen with conﬁrmedM. tuberculosis or histological, or
clinical evidence consistent with active EPTB, followed by a clinician's
decision to treat with TB chemotherapy [5].
CXR implies radiation exposure and has low speciﬁcity [6], while
SSM lacks sensitivity since the threshold of TB detection is high [7]. Fur-
thermore, SSM can only detect TB in patients in advanced stage; it is less
sensitive in Human Immunodeﬁciency Virus (HIV)-infected individuals,
anddoes not differentiate betweenMTBandnon-tuberculosismycobac-
terial (NTM) infection [8,9]. Culture currently is the reference standard
[5]. It needs only 10–100 MTB bacilli to establish a diagnosis, however,
the laboratory turn-around time is long (two to eight weeks) [1].
Other sputum-dependent tests have been developed more recently,
i.e. nucleic acid ampliﬁcation techniques which allow for fast identiﬁca-
tion of MTB as well as rapid assessment of rifampicin susceptibility
(such as GeneXpert® MTB/RIF (Cepheid, USA) and Truenat MTB
assays® (Molbio Diagnostics, India)), LPAs (Hain Lifescience, Germanythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
The standard tests to diagnose tuberculosis (TB) such as culture
and PCR, have high sensitivity, while sputum smear microscopy
has only moderate sensitivity. These tests are not point-of-care,
are sputum-dependent, and prone to laboratory fallacy, and need
trained laboratory personnel. There is increasing evidence that
analysis of exhaled breath could be used to diagnose TB. There
are two approaches to analyze breath specimens - chemical and
physical techniques. Examples of chemical techniques are gas
chromatography combined with mass spectrometry (GC/MS),
immunosensor and bio-optical technology, and electronic-nose
with sensors that identify chemical interactions between VOCs
and the sensor surfaces. The electronic nose has been used for di-
agnosis of various diseases, i.e. asthma, Chronic Obstructive Pul-
monary Disease (COPD), urinary tract infection, lung cancer, and
brain cancer. There has not been a systematic review regarding
the accuracy of electronic-nose equipment in diagnosing TB from
patients' breath. We explored the whole array or devices of breath
tests, including GC/MS, because there has been a rapid develop-
ment in this field since the previous review.
Added value of this study
This study provides evidence on the sensitivity and specificity of
breath test in diagnosing TB.
Implications of all the available evidence
These low to moderate strength of evidence studies show that an
electronic nose had high sensitivity and specificity, while other de-
vices had moderate to high sensitivity and low to moderate speci-
ficity. Further improvements are needed before breath test devices
can be introduced into the routine TB diagnostic work flow.
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anti-TB drugs, and TB LAMP (Eiken, Japan) for detection of TB [1]. How-
ever, LPAs and TB LAMP are not universally available or affordable, and
even though Xpert MTB/RIF is provided at reduced price for low-middle
income countries [1], it is not portable and needs stable electricity sup-
ply, limiting its use in highly burdened, remote settings in low- and
middle income countries.
One third of TB suspects have difﬁculty to collect an adequate quality
sputum sample [10]. Therefore, a non-sputumbased testwould be a tre-
mendous asset. Several non-sputum based tests are in development,
suchasurinary lipoarabinomannan forpatientswith TB-HIV coinfection,
computer-aided detection systems [1], pediatric stool processing prior
to Xpert [11], blood host marker, skin patches, and breath tests [12].
Breath tests have several advantages - non-invasive, potentially
point-of-care, easy-to-perform, fast, and convenient [13]. Infections
change the host metabolism producing distinct volatile organic com-
pounds (VOCs) [14], and Mycobacterium tuberculosis (MTB) produces
several VOCs [15–17], which can be detected from the breath. There
are two approaches to analyze breath specimens - chemical and
physical techniques. Examples of chemical techniques are gas
chromatography combined with mass spectrometry (GC/MS),
immunosensor and bio-optical technology, and electronic-nose with
sensors that identify chemical interactions between VOCs and the
sensor surfaces [18–23]. Physical techniques measure a physical
property of the molecule, such as Field Asymmetric Ion Mobility
Spectrometry (FAIMS) that measures movement of ionised moleculesof breath [24]. GC/MS requires complex equipment, operation
skills, and a well-conditioned environment, especially to record con-
centration differences of VOCs speciﬁc for TB [15–17,25,26], and dif-
ferent studies report different VOCs [17,25–27]. The electronic-nose
has an array of sensors that identiﬁes a pattern of VOCs without con-
sidering the speciﬁc composition of VOCs.
There has not been a systematic review regarding the accuracy of
electronic-nose equipment in diagnosing TB from patients' breath. We
also explored other types or devices of breath tests, such as GC/MS, be-
cause there has been a rapid development in thisﬁeld since theprevious
review [13].
To examine the accuracy of electronic-nose and other devices in di-
agnosing TB from patients' breath, we reviewed the diagnostic test ac-
curacy (DTA) studies that assessed the sensitivity and speciﬁcity of
electronic-nose and other devices in diagnosing TB in patients with TB
or suspected of having TB.
2. Methods
2.1. Protocol and registration
Methods of the analysis and inclusion criteria were documented in a
protocol, and registered in PROSPERO (CRD42019132895).
2.2. Eligibility criteria
We included the DTA studies with participants of any agewith TB or
suspicion of TB. Diagnosis of TB was based on the WHO guideline [5].
The index test was a breath test, the comparator being sputum smear
microscopy, chest radiography, culture, Gene Xpert, pleural biopsy, or
a Composite Reference Standard (CRS).
2.3. Information sources
Studieswere identiﬁed by searching electronic databases, i.e. Pubmed
(1946-present), Embase (1946-present),Webof Science (1946-present),
Medline (1946-present), clinicaltrials.gov, andWHO International Clini-
cal Trials Registry Platform (ICTRP). Cochrane database was also
reviewed. No limits were applied for language. The last search was run
on 6 January 2019. A.M.S. and D.D.P. conducted the search. We also
attempted to acquire anymissing information on results from the inves-
tigator of articles included in this review, i.e.Marcel Bruins [22,23].
2.4. Search strategy and selection criteria
The PRISMA statement was followed for the systematic search [28].
The search strategies used terms such as “tuberculosis”, “diagnosis,
“breath test”, “electronic nose”, and “volatile organic compound”.
Appendix 1 shows a detailed description of the search strategies. Studies
were included if the subject was human, andwere published from 1946
to present (6 January 2019). Abstracts of conferenceswere included.We
excluded unpublished data, duplicate studies, reviews, and case reports.
In addition, we hand-searched related articles from the reference lists,
and trials registries, i.e.clinicaltrials.gov and WHO ICTRP.
2.5. Study selection
Eligibility assessment of titles and abstractswas performed indepen-
dently by 2 investigators (A.M.S. and D.D.P.) based on the PICOS criteria
(Population = patients with TB or suspected with TB; Index test =
breath test by electronic nose or other devices; Comparator = other
tests for TB; Outcomes = sensitivity, speciﬁcity based on culture or
WHO guidelines for TB diagnosis if culture result was not available;
Study design: diagnostic test accuracy). Disagreements between inves-
tigators were resolved by consensus, or involving a third investigator
(T.S.W.) when consensus was not reached. Full-text articles were then
204 A.M.I. Saktiawati et al. / EBioMedicine 46 (2019) 202–214reviewed by A.M.S. and D.D.P. with a critical appraisal sheet taken from
Joanna Briggs Institute Reviewers' Manual 2015 [29] which was devel-
oped based on the Quality Assessment of Diagnostic Accuracy Studies
(QUADAS)-2 approach [30]. Resolving disagreements was conducted
in the samemanner. We then analysed the outcomes from the remain-
ing relevant research articles.2.6. Data collection process
A data extraction sheet was developed based on Joanna Briggs Insti-
tute Reviewers' Manual 2015 [29]. We pilot-tested it on ten randomly-
selected included studies, and reﬁned it accordingly. The two investiga-
tors (A.M.S. and D.D.P.) extracted the data from included studies.
Disagreements were resolved by discussion between the two investiga-
tors; if no agreement was reached, a third investigator (T.S.W.) was
involved.2.7. Data items
Information was extracted from each included study on: (1) charac-
teristics of study participants (demographic description, i.e. age, sex, in-
clusion and exclusion criteria; participant groups); (2) type of
intervention (breath test with electronic nose or other devices versus
other tests for TB); (3) type of outcome measures (sensitivity, speciﬁc-
ity); (4) funding sources.2.8. Risk of bias in individual studies
An assessment of risk of bias was conducted with the modiﬁed
version of the QUADAS tool for Cochrane reviews [31] in a blind
manner. Assessments were completed independently by two investi-
gators (A.M.S. and D.D.P.), and disagreements were resolved by con-
sensus, or involving a third investigator (T.S.W.) when consensus
was not reached.2.9. Summary measures and data analysis
The primary outcome measures were sensitivity and speciﬁcity of
breath test to diagnose TB using culture, or the criteria mentioned in
the WHO guideline for TB diagnosis if culture result was not available,
as the reference [5]. The secondary outcome measures were Positive
Likelihood Ratio (PLR), Negative Likelihood Ratio (NLR), and Diagnostic
Odds Ratio (DOR). Sensitivity was deﬁned as probability that a test re-
sult would be positive when the disease is present (true positive rate),
speciﬁcity was the probability that a test result would be negative
when the disease was absent (true negative rate). PLR described how
many times positive index test results were more likely in the diseased
group compared to control, NLR described how many times negative
index test results were less likely in the diseased group compared to
control, and DOR described how many times the odds were higher of
obtaining a test positive result in a diseased compared to control [32].
We calculated pooled sensitivity, speciﬁcity, PLR, NLR, and DOR with
95% conﬁdence intervals. We assessed heterogeneity and inconsistency
for the pooled estimates by the Cochrane Q and I2 statistic [33], and if
there was heterogeneity, we conducted subgroup analysis to ﬁnd the
sources [32]. We used bivariate hierarchical random effects logistic re-
gressionmodelsmethods formeta-analysis of DTA to generate the Sum-
mary Receiving Operator Characteristics (SROC) curve with point
estimates and their 95% conﬁdence region from all study sources. All
analyseswere performedwith STATA (version 15 SE; Stata Corporation,
College Station, TX, USA). Stata commands of “metandi” and
“metandiplot” are used to facilitate calculating the summary of the
ﬁtted point and the curve with 95% prediction region [34].2.10. Risk of bias across studies
Risk of bias was assessed according to QUADAS items [35]. We had
earlier planned tomake a funnel plot to assess the publication biaswithin
studies, but we decided not to, as it was not recommended by the
Cochrane Handbook considering that it might mislead the interpretation
of the publication bias assessment [32]. We also looked for missing data
from the included studies that could produce selective reporting bias.
3. Results
3.1. Study selection
A total of 14 studies were identiﬁed for inclusion in the review. The
search of Pubmed, Embase, Web of Science, Medline, clinicaltrials.gov,
ICTRP, and Cochrane databases provided a total of 391 studies. After
adjusting for duplicates, 239 remained. Of these, 225 studies were
discarded because these papers did not meet the criteria. The full text
of the remaining 20 studies was examined in more detail. Fourteen
studies met the inclusion criteria and were included in the systematic
review. By checking the references, relevant papers and searching for
studies that have cited these papers, no additional studies that met
the criteria for inclusion were identiﬁed.
3.2. Study characteristics
All fourteen studies ﬁnally selected for the reviewwere published in
English. Table 1 shows characteristics of the studies. Number of subjects
analysed ranged from 40 to 251 subjects per study. Only three studies
included children (aged ≥13 years); the others included only adults.
All studies were carried out prospectively, 9 out of 14 studies (64·3%)
employed a case-control study design (for studies that consisted of
training and validation phases, we only assessed the study design in
the validation phase as it reﬂected the performance of the device).
Most of them were conducted in hospitals and lung clinics; six studies
were conducted in Africa, two in Asia, two in South America, one in
Europe, two in transcontinental countries (Egypt and Russia), and one
in both Asia and Europe. (See Fig. 1.)
3.3. Risk of bias
Fig. 2 summarizes the risks of bias and applicability concerns of stud-
ies. Onlyﬁve studies speciﬁed that they involved consecutive series of pa-
tients; theother studiesdidnotdescribe theprocess of samplingandused
case-control study design. However, due to the nature of these pilot stud-
ies, case-control is commonly used, thus we assessed the risk of bias in
terms of ‘patient selection’ asmedium. All studies reported a clear deﬁni-
tion of a positive test using a reference diagnostic test, but only six en-
sured adequate blinding, six did not mention concealment, and the
subjects in the validation group in two studies overlappedwith the train-
ing group (medium to high risk of bias concerning ‘index test’). In terms
of ‘ﬂow and timing’, only six out of 14 studies mentioned the exact time
interval between the index test and reference test, but the sputumsample
could be collected anytime even on the sameday of the assessment using
the index test (low risk of bias). All of included studies had complete ver-
iﬁcation for positive reference test, however not all subjects in one study
used the same reference test. Eight studies used the gold standard, which
is culture, while other 6 studies also used other examinations beside cul-
ture (low tomedium risk of bias for reference standard). In summary, 12
studieswere consideredhavingamediumriskof bias or raisedapplicabil-
ity concerns for at least one item of the QUADAS-2 tool.
3.4. Test accuracy
The total number of subjects included in the analysis of sensitiv-
ity and speciﬁcity of breath tests (validation phase) amounted to
Table 1
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207A.M.I. Saktiawati et al. / EBioMedicine 46 (2019) 202–2141715 subjects (Table 1). The sensitivity and speciﬁcity of each test is
shown in Table 1. As the number of breath test devices other than
electronic-nose was insufﬁcient for grouping, the statistical analysis
was only calculated for the electronic-nose. The Q and I2 of
electronic-nose in diagnosing TB were p=0·23 and 0 (95% uncer-
tainty intervals:0–100), respectively. The pooled sensitivity and
speciﬁcity of electronic-nose in diagnosing TB were 0·92 (95%
CI:0·82–0·97) and 0·93 (95% CI:0·88–0·96), respectively (Fig. 3).
The PLR, NLR, and DOR were 13·4 (95% CI:7·2–24·9), 0·08 (95%
CI:0·03–0·20), and 162 (95% CI:41–634), respectively. Fig. 4 shows
the summary receiving operating characteristics for these studies.
The area under the curve (AUC) of electronic-nose was 0·97 (95%
CI:0·19–1·00). Meanwhile, the sensitivity and speciﬁcity of breath
test devices other than electronic nose ranged from 0·62 to 1·00,
and 0·11 to 0·84, respectively.4. Discussion
The pooled sensitivity and speciﬁcity of electronic-nose in diagnos-
ing TB, either pulmonary or extrapulmonary, were high. There is no
Fig. 2. Summary of QUADAS-2 assessments of included studies. Patient selection: describesmethods of patient selection; index text: describes the index test andhow itwas conducted and
interpreted; reference standard: describes the reference standard (gold standard test) and how it was conducted and interpreted; ﬂow and timing: describes any patients who did not
receive the index tests or reference standard or who were excluded from the 2 × 2 table, and describes the interval and any interventions between index tests and the reference
standard [30].
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Fig. 3. Paired forest plots of pooled sensitivity and speciﬁcity of electronic nose in diagnosing tuberculosis.
Fig. 4. Summary receiver operating characteristic (SROC) of electronic nose in diagnosing
tuberculosis.
209A.M.I. Saktiawati et al. / EBioMedicine 46 (2019) 202–214heterogeneity, indicating that the variability among studies that diag-
nose TB with electronic-nose was due to chance. Other devices had
moderate to high sensitivity and low to moderate speciﬁcity. The
strength of evidence within all 14 studies was low to moderate.
Five studies only included subjects representing two extreme sides of
the clinical spectrum of TB disease (healthy controls without any TB
symptoms, and symptomatic, treatment-naïve, smear positive pulmo-
nary TB cases) [18,21,36–38]. Meanwhile, different stages of TB disease
are characterized by dynamic metabolic changes within pathogen and
host and their interactions, thus different stages of TB diseasemay gener-
ate different breath test results [21]. In addition, around 20–25% of the
world population have latent TB [39], and the event of relapsed TB in
the high-TB burden countries is not uncommon. Therefore, these studies
had limited generalisability and clinical applicability, andmight also pro-
duce bias as the resultsmight be over-estimated, thus these assumptions
might be not valid for our review. Ideally, besides being able to identify
the VOCs produced by either the host or the bacteria, the breath test's
sensors should ideally be also able to identify different signals in different
stages of TB disease. Only seven studies included other pulmonary infec-
tions as controls [19,20,22,24,40–42], while a diagnostic test is typically
needed in this population, to identify the TB afﬂicted among the suspects.
Breath prints are inﬂuenced by various factors, which are divided into
physiological factors (age, sex, food, beverages), pathological and disease-
related conditions (smoking, comorbidities, medication), and sampling-
related issues (biaswith VOCs in the environment) [43]. Older age changed
breathprints inpatientswith lungcancer [44],maleshadhigher level of iso-
prene than females [45], several beverages and poultry meat could be
210 A.M.I. Saktiawati et al. / EBioMedicine 46 (2019) 202–214identiﬁed with an electronic-nose [46–50], and patients with high body
mass index (BMI) had more false-positive test results than patients with
normal or low BMI [23]. Smoking increased the levels of several VOCs, i.e.
benzene and pentane [51], while these two VOC markers were observed
in the culture and breath of TB patients [17]. Apart from those mentioned
factors, VOCs might be also inﬂuenced by genetic proﬁles [23]. Thus, in
the analysis of the breath test, confounding or modifying effects from
these factors should always be considered. In only four of the reviewed
studies, at least one of these factors were taken into account [18,21,23,37].
Furthermore, there were only three studies including children in their
study population, and children were also not exclusively enrolled
[18,22,40], while age may inﬂuence the breath test result [44].
In several electronic-nose studies, the exhaled breath was collected
into a bag/tube with the specimen investigated later [19,21,22,36].
Using bags for collection may be more useful in the ﬂow of healthcare in
a clinic, however, it might change the composition of the sample because
the VOCs bind with the sample-bag material, and the bag material re-
leases background emission of several pollutants [52]. Samples should
be also examined in six hours from the collection time [52], thus it adds
a burden and complicates the diagnostic process. As far as the portable
sensing technology is not yet speciﬁc enough for VOCs associated with
TB, we recommend to avoid using bags for sample collection. In addition,
although the sensors in anelectronic-nose cancaptureabundant amounts
of information,most of themdonot have sensitivity as high as other tech-
niques [53], thus to improve the sensitivity, pre-concentration tech-
niques, such as absorption of breath samples onto a solid phase, needs
to be performed. Several studies in this review used micro-extraction
(SPME) or Tenax as the pre-concentration technique [19,23,40], while
other studies did not mention it in their Methods section.
To develop a robust algorithm to enable real-timemeasurements, an
electronic-nose needs a prior knowledge of the data (training phase).
Ideally, to avoid a fallacy in breath test analysis due to confounding var-
iables, artefacts, and statistical errors, a training phase should include a
large number of study subjects, so that the number of subjects will be
bigger than the number of breath test variables/features, and the data
can be divided into a training and validation set [54]. However, if the
population is small, a leave-one-out cross validation is usually used in
the training phase, i.e. only one subject is used for validation purposes,
while the others are used for training [54]. The device performance can
be assessed more objectively if the next stage (validation phase) is car-
ried out in subjects who are not involved in the training phase. In only
three out of six studies with electronic-nose, the validation phase used
independent subjects from the training phase [19,21,36]. In addition, a
large number of subjects in the training phase is of great importance to
expose the device with large diversity in breath patterns from true-
positive study subjects. Only then, the device can recognize breath sam-
ples in the validation phase with high accuracy. For an electronic-nose
device, to match a pattern correctly, the pattern must be known before.
The diagnostic accuracy of an electronic-nose can only be determined
reliably if theTB status canbeclassiﬁedwithhighcertainty since theanal-
ysis of breath test completely depends on the correct classiﬁcation of the
study samples in the training phase. Therefore, a reference test should be
as ‘gold’ as possible, approaching the highest sensitivity and speciﬁcity.
When the gold standard is imperfect, the positive test results from an in-
vestigated diagnostic tool may be considered as false-positives, thus the
accuracy of this diagnostic tool will be underestimated. In this review,
eight studies used only culture as the reference test for diagnosing pul-
monary TB, while the other six studies used culture or other supporting
data when the culture result was negative. In our opinion, the use of
other supporting data to improve the accuracy of culture is justiﬁable be-
cause culture is also prone to laboratory error. In addition, follow-up
should be employed to ensure that the diagnosis made was correct. A
previous study has shown that follow-up could help to cover the weak-
ness of culture and improve its accuracy [55].
For other breath test devices, the selected ion ﬂow tube-mass spec-
trometry (SIFT-MS) becomes the preferable option as it is faster and hashigher sensitivity than GC–MS. [56] Ideally, the chemical platform for
chemical breath analysis would have online identiﬁcation of speciﬁc
analytes without the need for pre-concentration and should be able to
analyze small volatiles (in the ppt–ppq range) [53]. Currently with
GC–MS, samples still need to be pre-processed before testing. To vali-
date the biomarkers that were found through GC–MS or other spec-
trometries, a large cohort study is needed. The use of oral urea
administration in diagnosing TB may not be ideal because of low lung
concentration, and is confounded by the presence of H. pylori in the
gut [38]. However, the administration of urea by inhalation for diagnos-
ing TBwarrants investigation. Detection of antigen in coughwas shown
to have moderate sensitivity and speciﬁcity that was suspected as a re-
sult from the variation of antigen level in cough during the day, thus it
was suggested to conduct the breathalyzer test several times in a day
[20]. However, repeating a test several times in one day takes time
and is therefore impractical. Furthermore, prior to sputum collection,
patients needed to have nebulized therapy, thus limiting its use for a
point-of-care device in remote areas. This device might also be
projected as an add-on test for sputum smear microscopy, which
would not provide an advantage over sputum-dependent sputum
smear microscopy and culture.
The existing tests have high sensitivity, such as culture and PCR [1], or
very high speciﬁcity, such as Gene Xpert [57], or moderate sensitivity,
such as sputum smearmicroscopy [1,55]. However, these highly sensitive
tests are not point-of-care, are sputum-dependent, prone to laboratory
fallacy, and need trained laboratory personnel. With the high sensitivity,
easy operation, point-of-care, and hand-held form, the breath test
might be potentially used as a screening method rather than a diag-
nostic tool. Cases that are positive by breath test, could be referred
for the tests which are more speciﬁc, probably more expensive, and
laboratory-based, such as Gene Xpert. To date, there have been no
studies that investigate the breath test as a screening tool.
A challenge for the breath test development in the future is to detect
TB cases with negative sputum smear. Negative sputum smear was
shown to have correlation with a misdiagnosis of TB [55]. Another chal-
lenge is to investigate whether the breath test can accelerate the diag-
nostic process and lower its cost. A point-of-care automated thermal
desorption, gas chromatography and mass spectrometry (ATD-GC-
SAW) costs $20,000 [18], while an electronic-nose based on metal-
oxide sensors has an advantage of mass production at low cost. Analysis
of a breath VOC sample with a point-of-care ATD-GC-SAW takes six min
[18], whilst currently the analysis time with electronic-nose still takes
several days orweeks as the data needs to be sent to the device producer
before obtaining the diagnosis. Once the pattern recognition technique
algorithm is fully trained, the results should be generated automatically
in seconds. For further optimization of the sensors, speciﬁc VOCs in dif-
ferent stages of the disease need to be determined. The use of highly se-
lective sensors that target these VOCs may increase the sensitivity and
speciﬁcity. Finally, as the group of patients that need non-sputum-
based tests most are children, the sensitivity and speciﬁcity of breath
test exclusively in children needs to be extensively investigated.
Our review has some limitations. Only a limited number of studies
concerning breath test using electronic-nose for diagnosing TB were
available. Within the identiﬁed studies with breath test devices other
than electronic-nose, we were not able to conduct meta-analysis by the
type of devices because studies were few. Several studies only included
treatment-naïve, smear positive pulmonary TB cases, thus hindering
conclusions on the sensitivity and speciﬁcity of breath test for all stages
of TB, and this may introduce overestimation of sensitivity and speciﬁc-
ity. Nine out of 14 studies had an unclear risk of bias concerning patient
selection, and ﬁve had an applicability concern on one or two domains.
5. Conclusions
These low to moderate strength of evidence studies show that
breath tests have potential to screen for TB. However, it still needs
211A.M.I. Saktiawati et al. / EBioMedicine 46 (2019) 202–214further improvement, with a more robust trained pattern recognition
technique to give real-time measurements. An ideal breath test should
be accurate, fast, easy-to-use, point-of-care, and distributed with low
price, so that it can be used not only in clinics, but also for door-to-
door screening in remote areas, where TB diagnosis still faces great
challenges.
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